Jill Feldman: Ivy’s voice helped shape research and now her cells are helping to drive progress
Jill Feldman, Co-Founder of EGFR Resister, shared a post on LinkedIn:
“It’s hard to measure the impact we/advocates actually have on research.
This poster presented at AACR25 was a full circle moment. The study used a cell line based on paired molecular profiling of biopsies derived from my dear friend & fellow patient advocate Ivy Elkins after the cancer progressed in February 2023.
Dr Alvaro Guimaraes Paula & Dr John Heymach’s, at MD Anderson Cancer Center, goal was to help Ivy find a treatment sensitive to the rare resistance mechanism that drove the cancer to progress. Unfortunately, Ivy died before their research was completed, but her legacy lives on.
Ivy’s voice helped shape research, and now her cells are helping to drive progress – continuing her commitment to improve outcomes for patients.
Thank you Drs Heymach and Guimaraes, for recognizing and honoring Ivy’s memory and her contribution to research. There aren’t words to describe what this means to me/our community.”
More posts featuring Jill Feldman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023